Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55
Volume 55, Issue -, Pages 373-397Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010814-124438
Keywords
antiplatelet; anticoagulation; antithrombotic therapy; atherothrombosis; acute coronary syndrome; venous thromboembolism
Categories
Ask authors/readers for more resources
Ischemic heart disease and stroke are major causes of death and morbidity worldwide. Coronary and cerebrovascular events are a consequence of thrombus formation caused by atherosclerotic plaque rupture or embolism, both of which result from platelet activation and aggregation and thrombin-mediated fibrin generation via the coagulation cascade. Current and emerging antiplatelet and anticoagulant agents are evolving rapidly. The use of aspirin for primary prevention continues to be controversial, as are the doses appropriate for secondary prevention. Development of new oral and intravenous adenosine diphosphate P2Y(12) inhibitors and novel antiplatelet agents continues to transform the landscape of antiplatelet therapy. Oral anticoagulation has advanced with the use of direct thrombin and factor Xa inhibitors that do not require therapeutic monitoring. In this review, we discuss the pharmacology and growing clinical evidence for traditional and new antiplatelet and anticoagulant therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available